Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates


UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma

See more here:
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Related Posts